In advanced NSCLC, and in the absence of driver EGFR and ALK variants, a PD-L1 ≥1% cut-off is currently used to determine suitability for combination nivolumab/ipilimumab71 or pembrolizumab monotherapy13,72; and a PD-L1 ≥50% cut-off is used to determine suitability for atezolizumab monotherapy51 or cemiplimab monotherapy92. This evidence concerns the gene CD274 and non-small cell lung carcinoma.